Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of ESSA Pharma Inc. from 30 Sep 2019 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
ESSA Pharma Inc. annual and quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 30 Sep 2019 to 30 Sep 2024.
  • ESSA Pharma Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Jun 2024 was $7,233,747, a 0.89% increase year-over-year.
  • ESSA Pharma Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $28,542,821, a 7.4% decline from 2023.
  • ESSA Pharma Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $26,580,743, a 25% increase from 2022.
  • ESSA Pharma Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $35,215,072, a 4.4% increase from 2021.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Change (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)

ESSA Pharma Inc. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $28,542,821 -$1,962,078 -7.4% 01 Oct 2023 30 Sep 2024 10-K 17 Dec 2024 2024 FY
2023 $26,580,743 +$8,634,329 +25% 01 Oct 2022 30 Sep 2023 10-K 17 Dec 2024 2024 FY
2022 $35,215,072 +$1,624,738 +4.4% 01 Oct 2021 30 Sep 2022 10-K 12 Dec 2023 2023 FY
2021 $36,839,810 -$13,105,793 -55% 01 Oct 2020 30 Sep 2021 10-K 13 Dec 2022 2022 FY
2020 $23,734,017 -$11,015,105 -87% 01 Oct 2019 30 Sep 2020 10-K 18 Nov 2021 2021 FY
2019 $12,718,912 01 Oct 2018 30 Sep 2019 10-K 18 Nov 2021 2021 FY

ESSA Pharma Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 $7,233,747 +$65,126 +0.89% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2024 2024 Q3
Q1 2024 $8,989,535 -$1,930,896 -27% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2024 2024 Q2
Q3 2023 $26,580,743 $5,481,349 +$908,790 +14% 01 Jul 2023 30 Sep 2023 10-K 17 Dec 2024 2024 FY
Q2 2023 $27,489,533 $7,298,873 +$1,573,637 +18% 01 Apr 2023 30 Jun 2023 10-Q 05 Aug 2024 2024 Q3
Q1 2023 $29,063,170 $7,058,639 +$3,795,965 +35% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q2
Q4 2022 $32,859,135 $6,741,882 +$2,355,937 +26% 01 Oct 2022 31 Dec 2022 10-Q 07 Feb 2023 2022 Q1
Q3 2022 $35,215,072 $6,390,139 +$2,169,360 +25% 01 Jul 2022 30 Sep 2022 10-K 12 Dec 2023 2023 FY
Q2 2022 $37,384,432 $8,872,510 -$121,299 -1.4% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q3
Q1 2022 $37,263,133 $10,854,604 +$2,110,643 +16% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q2
Q4 2021 $39,373,776 $9,097,819 -$2,533,966 -39% 01 Oct 2021 31 Dec 2021 10-Q 07 Feb 2023 2022 Q1
Q3 2021 $36,839,810 $8,559,499 -$3,991,510 -87% 01 Jul 2021 30 Sep 2021 10-K 13 Dec 2022 2022 FY
Q2 2021 $32,848,300 $8,751,211 -$3,826,383 -78% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q3
Q1 2021 $29,021,917 $12,965,247 -$3,615,320 -39% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q2
Q4 2020 $25,406,597 $6,563,853 -$1,672,580 -34% 01 Oct 2020 31 Dec 2020 10-Q 03 Feb 2022 2022 Q1
Q3 2020 $23,734,017 $4,567,989 01 Jul 2020 30 Sep 2020 10-K 18 Nov 2021 2021 FY
Q2 2020 $4,924,828 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q3
Q1 2020 $9,349,927 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q2
Q4 2019 $4,891,273 01 Oct 2019 31 Dec 2019 10-Q 11 Feb 2021 2021 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.